Successful treatment of a PNH patient non-responsive to eculizumab with the novel complement C5 inhibitor coversin (nomacopan)

Saskia Schols, Miles A Nunn, Ian Mackie, Wynne Weston-Davies, Jun-Ichi Nishimura, Yuzuru Kanakura, Nicole Blijlevens, Petra Muus, Saskia Langemeijer, Saskia Schols, Miles A Nunn, Ian Mackie, Wynne Weston-Davies, Jun-Ichi Nishimura, Yuzuru Kanakura, Nicole Blijlevens, Petra Muus, Saskia Langemeijer

No abstract available

Keywords: complement; coversin; haemolysis; nomacopan; paroxysmal nocturnal haemoglobinuria.

References

    1. Brodsky, R.A., Young, N.S., Antonioli, E., Risitano, A.M., Schrezenmeier, H., Schubert, J., Gaya, A., Coyle, L., de Castro, C., Fu, C.L., Maciejewski, J.P., Bessler, M., Kroon, H.A., Rother, R.P. & Hillmen, P. (2008) Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood, 111, 1840-1847.
    1. Goodship, T.H.J., Pinto, F., Weston-Davies, W.H., Silva, J., Nishimura, J.I., Nunn, M.A., Mackie, I., Machin, S.J., Palm, L., Pryce, J.W., Chiesa, R., Amrolia, P. & Veys, P. (2017) Use of the complement inhibitor Coversin to treat HSCT-associated TMA. Blood Advances, 1, 1254-1258.
    1. Hillmen, P., Hall, C., Marsh, J.C., Elebute, M., Bombara, M.P., Petro, B.E., Cullen, M.J., Richards, S.J., Rollins, S.A., Mojcik, C.F. & Rother, R.P. (2004) Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. New England Journal of Medicine, 350, 552-559.
    1. Hillmen, P., Young, N.S., Schubert, J., Brodsky, R.A., Socie, G., Muus, P., Roth, A., Szer, J., Elebute, M.O., Nakamura, R., Browne, P., Risitano, A.M., Hill, A., Schrezenmeier, H., Fu, C.L., Maciejewski, J., Rollins, S.A., Mojcik, C.F., Rother, R.P. & Luzzatto, L. (2006) The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. New England Journal of Medicine, 355, 1233-1243.
    1. Hillmen, P., Muus, P., Duhrsen, U., Risitano, A.M., Schubert, J., Luzzatto, L., Schrezenmeier, H., Szer, J., Brodsky, R.A., Hill, A., Socie, G., Bessler, M., Rollins, S.A., Bell, L., Rother, R.P. & Young, N.S. (2007) Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood, 110, 4123-4128.
    1. Jore, M.M., Johnson, S., Sheppard, D., Barber, N.M., Li, Y.I., Nunn, M.A., Elmlund, H. & Lea, S.M. (2016) Structural basis for therapeutic inhibition of complement C5. Nature Structural & Molecular Biology, 23, 378-386.
    1. Kelly, R.J., Hill, A., Arnold, L.M., Brooksbank, G.L., Richards, S.J., Cullen, M., Mitchell, L.D., Cohen, D.R., Gregory, W.M. & Hillmen, P. (2011) Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood, 117, 6786-6792.
    1. Nishimura, J., Yamamoto, M., Hayashi, S., Ohyashiki, K., Ando, K., Brodsky, A.L., Noji, H., Kitamura, K., Eto, T., Takahashi, T., Masuko, M., Matsumoto, T., Wano, Y., Shichishima, T., Shibayama, H., Hase, M., Li, L., Johnson, K., Lazarowski, A., Tamburini, P., Inazawa, J., Kinoshita, T. & Kanakura, Y. (2014) Genetic variants in C5 and poor response to eculizumab. New England Journal of Medicine, 370, 632-639.
    1. Notaro, R. & Sica, M. (2018) C3-mediated extravascular hemolysis in PNH on eculizumab: Mechanism and clinical implications. Seminars in Hematology, 55, 130-135.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する